NOVEL ANTI-IL 13 ANTIBODIES AND USES THEREOF
Antagonističko protutijelo protiv ljudskog IL-13, ili njegov antigenski vežući fragment, koje se specifično veže na ljudski IL13, naznačeno time što navedeno protutijelo kompetitivno inhibira vezanje protutijela kojeg proizvodi hibridom 228B/C-1, kojem je pridružen ATCC depozitni broj PTA-5657, na I...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | Croatian English |
Published |
31.05.2012
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Antagonističko protutijelo protiv ljudskog IL-13, ili njegov antigenski vežući fragment, koje se specifično veže na ljudski IL13, naznačeno time što navedeno protutijelo kompetitivno inhibira vezanje protutijela kojeg proizvodi hibridom 228B/C-1, kojem je pridružen ATCC depozitni broj PTA-5657, na IL-13.Patent sadrži još 29 patentnih zahtjeva.
The present invention relates to ant-IL-13 antibodies that bind specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does not bind mouse IL13, and neutralize human IL13 activity at an approximate molar ratio of 1:2 (MAb:IL13). The invention also relates to the use of these antibodies in the treatment of IL13-mediated diseases, such as allergic disease, including asthma, allergic asthma, non-allergic (intrinsic) asthma, allergic rhinitis, atopic dermatitis, allergic conjunctivitis, eczema, urticaria, food allergies, chronic obstructive pulmonary disease, ulcerative colitis, RSV infection, uveitis, scleroderma, and osteoporosis. |
---|---|
Bibliography: | Application Number: HR2012P000376T |